Cargando…
Melatonin and urological cancers: a new therapeutic approach
Urological cancers are responsible for thousands of cancer-related deaths around the world. Despite all developments in therapeutic approaches for cancer therapy, the absence of efficient treatments is a critical and vital problematic issue for physicians and researchers. Furthermore, routine medica...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488244/ https://www.ncbi.nlm.nih.gov/pubmed/32943992 http://dx.doi.org/10.1186/s12935-020-01531-1 |
_version_ | 1783581654643638272 |
---|---|
author | Mehrzadi, Mohammad Hossein Hosseinzadeh, Azam Juybari, Kobra Bahrampour Mehrzadi, Saeed |
author_facet | Mehrzadi, Mohammad Hossein Hosseinzadeh, Azam Juybari, Kobra Bahrampour Mehrzadi, Saeed |
author_sort | Mehrzadi, Mohammad Hossein |
collection | PubMed |
description | Urological cancers are responsible for thousands of cancer-related deaths around the world. Despite all developments in therapeutic approaches for cancer therapy, the absence of efficient treatments is a critical and vital problematic issue for physicians and researchers. Furthermore, routine medical therapies contribute to several undesirable adverse events for patients, reducing life quality and survival time. Therefore, many attempts are needed to explore potent alternative or complementary treatments for great outcomes. Melatonin has multiple beneficial potential effects, including anticancer properties. Melatonin in combination with chemoradiation therapy or even alone could suppress urological cancers through affecting essential cellular pathways. This review discusses current evidence reporting the beneficial effect of melatonin in urological malignancies, including prostate cancer, bladder cancer, and renal cancer. |
format | Online Article Text |
id | pubmed-7488244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74882442020-09-16 Melatonin and urological cancers: a new therapeutic approach Mehrzadi, Mohammad Hossein Hosseinzadeh, Azam Juybari, Kobra Bahrampour Mehrzadi, Saeed Cancer Cell Int Review Urological cancers are responsible for thousands of cancer-related deaths around the world. Despite all developments in therapeutic approaches for cancer therapy, the absence of efficient treatments is a critical and vital problematic issue for physicians and researchers. Furthermore, routine medical therapies contribute to several undesirable adverse events for patients, reducing life quality and survival time. Therefore, many attempts are needed to explore potent alternative or complementary treatments for great outcomes. Melatonin has multiple beneficial potential effects, including anticancer properties. Melatonin in combination with chemoradiation therapy or even alone could suppress urological cancers through affecting essential cellular pathways. This review discusses current evidence reporting the beneficial effect of melatonin in urological malignancies, including prostate cancer, bladder cancer, and renal cancer. BioMed Central 2020-09-10 /pmc/articles/PMC7488244/ /pubmed/32943992 http://dx.doi.org/10.1186/s12935-020-01531-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Mehrzadi, Mohammad Hossein Hosseinzadeh, Azam Juybari, Kobra Bahrampour Mehrzadi, Saeed Melatonin and urological cancers: a new therapeutic approach |
title |
Melatonin and urological cancers: a new therapeutic approach |
title_full |
Melatonin and urological cancers: a new therapeutic approach |
title_fullStr |
Melatonin and urological cancers: a new therapeutic approach |
title_full_unstemmed |
Melatonin and urological cancers: a new therapeutic approach |
title_short |
Melatonin and urological cancers: a new therapeutic approach |
title_sort | melatonin and urological cancers: a new therapeutic approach |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488244/ https://www.ncbi.nlm.nih.gov/pubmed/32943992 http://dx.doi.org/10.1186/s12935-020-01531-1 |
work_keys_str_mv | AT mehrzadimohammadhossein melatoninandurologicalcancersanewtherapeuticapproach AT hosseinzadehazam melatoninandurologicalcancersanewtherapeuticapproach AT juybarikobrabahrampour melatoninandurologicalcancersanewtherapeuticapproach AT mehrzadisaeed melatoninandurologicalcancersanewtherapeuticapproach |